These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24360324)

  • 21. [Chronic autoimmune urticaria: treatment with omalizumab].
    Máspero JF; Parisi CA; De Gennaro M; Benhabib O; Lampert M
    Arch Argent Pediatr; 2009 Oct; 107(5):452-6. PubMed ID: 19809768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promising option in the prevention of idiopathic anaphylaxis: omalizumab.
    Demirtürk M; Gelincik A; Colakoğlu B; Dal M; Büyüköztürk S
    J Dermatol; 2012 Jun; 39(6):552-4. PubMed ID: 22390871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab in chronic urticaria.
    Metz M; Maurer M
    Curr Opin Allergy Clin Immunol; 2012 Aug; 12(4):406-11. PubMed ID: 22766620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologic agents and the therapy of chronic spontaneous urticaria.
    Kaplan AP; Popov TA
    Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):347-53. PubMed ID: 24936849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab.
    von Websky A; Reich K; Steinkraus V; Breuer K
    J Dtsch Dermatol Ges; 2013 Jul; 11(7):677-8. PubMed ID: 23575040
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E.
    Quist SR; Ambach A; Göppner D; Quist J; Franke I; Bonnekoh B; Gollnick HP
    Acta Derm Venereol; 2013 Mar; 93(2):206-8. PubMed ID: 23042516
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic urticaria: omalizumab and review of therapeutic options.
    Bergstrom KG
    J Drugs Dermatol; 2013 Jun; 12(6):715-6. PubMed ID: 23839196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.
    Song CH; Stern S; Giruparajah M; Berlin N; Sussman GL
    Ann Allergy Asthma Immunol; 2013 Feb; 110(2):113-7. PubMed ID: 23352531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential role of omalizumab in the treatment of chronic urticaria.
    Stitt JM; Dreskin SC
    Immunotherapy; 2014; 6(6):691-7. PubMed ID: 25186602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria.
    Metz M; Ohanyan T; Church MK; Maurer M
    JAMA Dermatol; 2014 Mar; 150(3):288-90. PubMed ID: 24477320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omalizumab (Xolair) for the treatment of chronic idiopathic urticarial.
    Scheinfeld N
    Skinmed; 2014; 12(5):294-7. PubMed ID: 25632648
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice.
    Labrador-Horrillo M; Valero A; Velasco M; Jáuregui I; Sastre J; Bartra J; Silvestre JF; Ortiz de Frutos J; Gimenez-Arnau A; Ferrer M
    Expert Opin Biol Ther; 2013 Sep; 13(9):1225-8. PubMed ID: 23875845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imported fire ant rush desensitization using omalizumab and a premedication regimen.
    Tille KS; Parker AL
    Ann Allergy Asthma Immunol; 2014 Nov; 113(5):574-6. PubMed ID: 25216971
    [No Abstract]   [Full Text] [Related]  

  • 35. Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis.
    Kai AC; Flohr C; Grattan CE
    Clin Exp Dermatol; 2014 Jul; 39(5):651-2. PubMed ID: 24758481
    [No Abstract]   [Full Text] [Related]  

  • 36. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab.
    Vestergaard C; Deleuran M
    Acta Derm Venereol; 2010 Jul; 90(4):443-4. PubMed ID: 20574627
    [No Abstract]   [Full Text] [Related]  

  • 37. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.
    Lang DM
    Ann Allergy Asthma Immunol; 2014 Apr; 112(4):276-9. PubMed ID: 24589165
    [No Abstract]   [Full Text] [Related]  

  • 38. [Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance].
    Klyucheva M; von Berg A; Gappa M; Suerbaum C; Berdel D
    Pneumologie; 2013 Apr; 67(4):233-7. PubMed ID: 23576201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.
    Guillén D; Bobolea I; Calderon O; Fiandor A; Cabañas R ; Heredia R; Quirce S
    J Investig Allergol Clin Immunol; 2015; 25(2):133-5. PubMed ID: 25997307
    [No Abstract]   [Full Text] [Related]  

  • 40. Omalizumab is efficacious for management of recalcitrant, antihistamine-resistant chronic urticaria.
    Lang DM
    Drugs Today (Barc); 2015 Jun; 51(6):367-74. PubMed ID: 26261850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.